Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pleural Effusion, Malignant 3Immunoglobulin Light-chain Amyloidosis 3Colorectal Neoplasms 3Breast Neoplasms 3Mycosis Fungoides 2Lymphoma, Non-Hodgkin 2Amyloidosis 2Waldenstrom Macroglobulinemia 1Urologic Neoplasms 1Tuberous Sclerosis 1Tissue Adhesions 1Skin Toxicity 1Sezary Syndrome 1Ras-wildtype Colorectal Cancer 1Polyps 1Polycystic Ovary Syndrome 1Pleural Neoplasms 1Pancreatic Neoplasms 1Pain 1Neurofibromatosis 2 1Neoplasms, Second Primary 1Myoma 1Menstruation Disturbances 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1

Interventions

Carboplatin 330Pemetrexed 266Cisplatin 234Docetaxel 195Paclitaxel 182Radiotherapy 181Erlotinib Hydrochloride 153pembrolizumab 147Gemcitabine 147Bevacizumab 125Drug Therapy 121Radiosurgery 115Nivolumab 112osimertinib 92durvalumab 88Gefitinib 67atezolizumab 63Vinorelbine 63Surgical Procedures, Operative 62Magnetic Resonance Spectroscopy 54anlotinib 42Immunotherapy 42Taxes 39Blood Specimen Collection 39Ipilimumab 38130-nm albumin-bound paclitaxel 38Specimen Handling 36Immune Checkpoint Inhibitors 35Radiation 34Albumin-Bound Paclitaxel 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Non-Small-Cell Lung × Doxycycline × Clear all
NCT00803842 2015-02-26

Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced Rash

Northwestern University

Phase NA Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Exanthema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡